| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 77 | 2023 | 4660 | 4.250 |
Why?
|
| Cystadenocarcinoma, Serous | 23 | 2022 | 487 | 3.170 |
Why?
|
| Genital Neoplasms, Female | 23 | 2022 | 741 | 2.590 |
Why?
|
| Peritoneal Neoplasms | 15 | 2022 | 828 | 1.980 |
Why?
|
| Uterine Cervical Neoplasms | 24 | 2022 | 1833 | 1.710 |
Why?
|
| Endometrial Neoplasms | 21 | 2022 | 1341 | 1.250 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 10 | 2019 | 469 | 1.120 |
Why?
|
| Patient Preference | 3 | 2019 | 221 | 1.100 |
Why?
|
| Patient Satisfaction | 9 | 2019 | 928 | 1.030 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 4 | 2017 | 108 | 0.950 |
Why?
|
| Aromatase Inhibitors | 3 | 2022 | 305 | 0.840 |
Why?
|
| Cytoreduction Surgical Procedures | 9 | 2023 | 475 | 0.740 |
Why?
|
| Female | 162 | 2023 | 142310 | 0.720 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2020 | 839 | 0.700 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2015 | 1215 | 0.680 |
Why?
|
| Middle Aged | 121 | 2022 | 86512 | 0.660 |
Why?
|
| Genetic Testing | 8 | 2019 | 1587 | 0.660 |
Why?
|
| Hysterectomy | 12 | 2019 | 616 | 0.620 |
Why?
|
| Adult | 108 | 2022 | 78150 | 0.610 |
Why?
|
| Aged | 96 | 2023 | 70370 | 0.610 |
Why?
|
| Quality of Life | 17 | 2023 | 4579 | 0.610 |
Why?
|
| Endometrial Hyperplasia | 4 | 2020 | 112 | 0.610 |
Why?
|
| Healthcare Disparities | 4 | 2018 | 601 | 0.600 |
Why?
|
| Health Status | 2 | 2014 | 604 | 0.600 |
Why?
|
| Spirituality | 3 | 2014 | 128 | 0.570 |
Why?
|
| Carcinoma, Endometrioid | 7 | 2020 | 324 | 0.570 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2017 | 587 | 0.560 |
Why?
|
| Carcinoma | 8 | 2018 | 2583 | 0.560 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 203 | 0.540 |
Why?
|
| Ovariectomy | 6 | 2018 | 330 | 0.530 |
Why?
|
| Medicare | 5 | 2023 | 896 | 0.510 |
Why?
|
| Peritoneum | 3 | 2022 | 150 | 0.510 |
Why?
|
| Humans | 165 | 2023 | 262350 | 0.510 |
Why?
|
| Watchful Waiting | 1 | 2017 | 289 | 0.500 |
Why?
|
| Internal-External Control | 4 | 2017 | 110 | 0.490 |
Why?
|
| Anxiety | 7 | 2016 | 1190 | 0.490 |
Why?
|
| Young Adult | 35 | 2020 | 21506 | 0.490 |
Why?
|
| Vulnerable Populations | 1 | 2015 | 172 | 0.470 |
Why?
|
| Gynecologic Surgical Procedures | 6 | 2019 | 361 | 0.470 |
Why?
|
| Fallopian Tube Neoplasms | 5 | 2018 | 153 | 0.450 |
Why?
|
| Health Services Accessibility | 3 | 2015 | 763 | 0.440 |
Why?
|
| Neoplasm Grading | 10 | 2020 | 1751 | 0.420 |
Why?
|
| Aged, 80 and over | 48 | 2023 | 30000 | 0.420 |
Why?
|
| Perception | 2 | 2013 | 352 | 0.410 |
Why?
|
| Religion | 2 | 2013 | 90 | 0.400 |
Why?
|
| Advance Care Planning | 3 | 2017 | 86 | 0.380 |
Why?
|
| Retrospective Studies | 48 | 2022 | 38028 | 0.370 |
Why?
|
| Neoplasm Staging | 27 | 2021 | 13674 | 0.370 |
Why?
|
| Adenocarcinoma | 14 | 2018 | 7793 | 0.370 |
Why?
|
| Adenocarcinoma, Clear Cell | 4 | 2017 | 177 | 0.360 |
Why?
|
| Sexuality | 2 | 2006 | 40 | 0.350 |
Why?
|
| Genes, BRCA2 | 6 | 2017 | 309 | 0.350 |
Why?
|
| Primary Health Care | 1 | 2015 | 790 | 0.340 |
Why?
|
| Disease-Free Survival | 15 | 2023 | 10025 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2023 | 15882 | 0.340 |
Why?
|
| Genes, BRCA1 | 6 | 2017 | 387 | 0.340 |
Why?
|
| Surveys and Questionnaires | 15 | 2019 | 5713 | 0.340 |
Why?
|
| Neoplasms, Glandular and Epithelial | 4 | 2017 | 520 | 0.340 |
Why?
|
| Cystadenocarcinoma, Papillary | 3 | 2022 | 82 | 0.330 |
Why?
|
| Medical Oncology | 3 | 2011 | 1425 | 0.320 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 1305 | 0.310 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 928 | 0.310 |
Why?
|
| Burnout, Professional | 1 | 2011 | 204 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2022 | 10074 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 14 | 2023 | 4980 | 0.310 |
Why?
|
| Uterine Neoplasms | 4 | 2016 | 549 | 0.300 |
Why?
|
| Early Detection of Cancer | 6 | 2016 | 1267 | 0.300 |
Why?
|
| Risk Reduction Behavior | 4 | 2018 | 228 | 0.300 |
Why?
|
| United States | 24 | 2023 | 15563 | 0.300 |
Why?
|
| Attitude to Health | 3 | 2019 | 466 | 0.300 |
Why?
|
| Tamoxifen | 3 | 2020 | 875 | 0.300 |
Why?
|
| BRCA2 Protein | 3 | 2018 | 359 | 0.290 |
Why?
|
| Combined Modality Therapy | 7 | 2014 | 8887 | 0.280 |
Why?
|
| SEER Program | 9 | 2022 | 1000 | 0.280 |
Why?
|
| Laparoscopy | 5 | 2021 | 1230 | 0.280 |
Why?
|
| CA-125 Antigen | 3 | 2020 | 226 | 0.280 |
Why?
|
| Obesity | 6 | 2019 | 2892 | 0.280 |
Why?
|
| Salpingectomy | 2 | 2018 | 43 | 0.280 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2020 | 275 | 0.270 |
Why?
|
| Cohort Studies | 17 | 2021 | 9293 | 0.270 |
Why?
|
| BRCA1 Protein | 3 | 2018 | 495 | 0.270 |
Why?
|
| Pancreaticoduodenectomy | 7 | 2010 | 692 | 0.260 |
Why?
|
| Smoking | 2 | 2014 | 2444 | 0.260 |
Why?
|
| Uterine Hemorrhage | 2 | 2016 | 59 | 0.260 |
Why?
|
| Decision Making | 4 | 2011 | 1295 | 0.260 |
Why?
|
| Insurance Claim Review | 2 | 2022 | 72 | 0.250 |
Why?
|
| Vomiting | 3 | 2014 | 354 | 0.240 |
Why?
|
| Platinum Compounds | 3 | 2017 | 131 | 0.230 |
Why?
|
| Survival Rate | 16 | 2018 | 12243 | 0.230 |
Why?
|
| Carcinosarcoma | 2 | 2017 | 146 | 0.220 |
Why?
|
| Palliative Care | 5 | 2015 | 2032 | 0.220 |
Why?
|
| Genetic Counseling | 4 | 2018 | 380 | 0.210 |
Why?
|
| Nausea | 4 | 2015 | 525 | 0.210 |
Why?
|
| Symptom Assessment | 2 | 2015 | 270 | 0.210 |
Why?
|
| Lymph Node Excision | 9 | 2018 | 1960 | 0.210 |
Why?
|
| Mental Health | 2 | 2017 | 409 | 0.200 |
Why?
|
| Body Mass Index | 7 | 2020 | 2213 | 0.200 |
Why?
|
| Texas | 9 | 2016 | 6308 | 0.200 |
Why?
|
| Health Care Costs | 5 | 2019 | 677 | 0.200 |
Why?
|
| Terminal Care | 2 | 2017 | 446 | 0.200 |
Why?
|
| Cost Sharing | 1 | 2021 | 10 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2023 | 3892 | 0.190 |
Why?
|
| Medicaid | 4 | 2022 | 286 | 0.190 |
Why?
|
| Schools | 1 | 2022 | 233 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2014 | 5435 | 0.190 |
Why?
|
| Adaptation, Psychological | 3 | 2014 | 763 | 0.190 |
Why?
|
| Mutation | 9 | 2022 | 15186 | 0.190 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2020 | 33 | 0.190 |
Why?
|
| Health Expenditures | 2 | 2021 | 211 | 0.180 |
Why?
|
| Levonorgestrel | 1 | 2020 | 49 | 0.180 |
Why?
|
| Deoxycytidine | 5 | 2017 | 1360 | 0.180 |
Why?
|
| Prognosis | 17 | 2018 | 21746 | 0.180 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 293 | 0.180 |
Why?
|
| Pain Measurement | 3 | 2014 | 983 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2004 | 599 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2022 | 803 | 0.170 |
Why?
|
| Live Birth | 1 | 2019 | 56 | 0.170 |
Why?
|
| Postoperative Complications | 11 | 2019 | 5565 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2019 | 5540 | 0.170 |
Why?
|
| Pregnancy Rate | 1 | 2019 | 56 | 0.170 |
Why?
|
| Receptors, Progesterone | 4 | 2020 | 1388 | 0.170 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2021 | 482 | 0.170 |
Why?
|
| Hospitals, County | 1 | 2018 | 29 | 0.170 |
Why?
|
| Gynecology | 2 | 2012 | 220 | 0.170 |
Why?
|
| Fertility Preservation | 2 | 2019 | 150 | 0.170 |
Why?
|
| Body Weight | 3 | 2016 | 1292 | 0.170 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2011 | 221 | 0.170 |
Why?
|
| Age Factors | 9 | 2018 | 5387 | 0.160 |
Why?
|
| Advance Directives | 2 | 2016 | 88 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 7 | 2010 | 5101 | 0.160 |
Why?
|
| Adolescent | 19 | 2019 | 31279 | 0.160 |
Why?
|
| Patient Participation | 3 | 2017 | 463 | 0.160 |
Why?
|
| Ovary | 3 | 2015 | 669 | 0.160 |
Why?
|
| Prospective Studies | 11 | 2018 | 12925 | 0.160 |
Why?
|
| Risk Management | 1 | 2019 | 107 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2013 | 1301 | 0.160 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2019 | 101 | 0.160 |
Why?
|
| Sentinel Lymph Node | 2 | 2018 | 217 | 0.160 |
Why?
|
| Antineoplastic Agents | 13 | 2020 | 14304 | 0.160 |
Why?
|
| Patient Outcome Assessment | 1 | 2019 | 247 | 0.150 |
Why?
|
| Pelvic Exenteration | 1 | 2018 | 108 | 0.150 |
Why?
|
| Psychometrics | 3 | 2017 | 947 | 0.150 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 14910 | 0.150 |
Why?
|
| Cost-Benefit Analysis | 7 | 2021 | 948 | 0.150 |
Why?
|
| Intra-Abdominal Fat | 1 | 2018 | 95 | 0.150 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 1 | 2017 | 27 | 0.150 |
Why?
|
| Postmenopause | 2 | 2016 | 377 | 0.150 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2017 | 55 | 0.150 |
Why?
|
| Leuprolide | 1 | 2017 | 65 | 0.140 |
Why?
|
| Blood Loss, Surgical | 3 | 2008 | 312 | 0.140 |
Why?
|
| Risk Factors | 14 | 2023 | 17611 | 0.140 |
Why?
|
| Length of Stay | 5 | 2019 | 1929 | 0.140 |
Why?
|
| Vaginal Discharge | 1 | 2016 | 9 | 0.140 |
Why?
|
| Time Factors | 12 | 2021 | 12983 | 0.140 |
Why?
|
| Colorectal Neoplasms | 3 | 2022 | 3583 | 0.140 |
Why?
|
| Lymphatic Vessels | 1 | 2017 | 143 | 0.140 |
Why?
|
| Obesity, Morbid | 2 | 2017 | 227 | 0.140 |
Why?
|
| Breast Neoplasms | 9 | 2010 | 15708 | 0.140 |
Why?
|
| Adiposity | 1 | 2018 | 238 | 0.140 |
Why?
|
| Automobiles | 1 | 2015 | 9 | 0.140 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 456 | 0.140 |
Why?
|
| Receptors, Estrogen | 3 | 2020 | 2084 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 245 | 0.130 |
Why?
|
| Insurance Coverage | 3 | 2022 | 256 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 490 | 0.130 |
Why?
|
| Survivors | 2 | 2015 | 1034 | 0.130 |
Why?
|
| Safety-net Providers | 1 | 2015 | 53 | 0.130 |
Why?
|
| Vaginal Neoplasms | 2 | 2010 | 148 | 0.130 |
Why?
|
| Lymph Nodes | 4 | 2017 | 2969 | 0.130 |
Why?
|
| Health Behavior | 1 | 2019 | 602 | 0.130 |
Why?
|
| Poverty | 1 | 2018 | 472 | 0.130 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 202 | 0.130 |
Why?
|
| Physicians | 3 | 2013 | 881 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 182 | 0.130 |
Why?
|
| Mind-Body Therapies | 1 | 2014 | 28 | 0.120 |
Why?
|
| Documentation | 1 | 2016 | 207 | 0.120 |
Why?
|
| Taxoids | 4 | 2020 | 970 | 0.120 |
Why?
|
| Health Literacy | 1 | 2015 | 121 | 0.120 |
Why?
|
| Treatment Outcome | 16 | 2020 | 33024 | 0.120 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 146 | 0.120 |
Why?
|
| Fear | 1 | 2015 | 255 | 0.120 |
Why?
|
| Cystadenoma, Serous | 1 | 2013 | 29 | 0.120 |
Why?
|
| Breast | 1 | 2020 | 1350 | 0.120 |
Why?
|
| Holistic Health | 1 | 2013 | 11 | 0.120 |
Why?
|
| Piperazines | 4 | 2021 | 2098 | 0.110 |
Why?
|
| Neoplasms | 4 | 2017 | 15206 | 0.110 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2018 | 1417 | 0.110 |
Why?
|
| Leiomyoma | 1 | 2014 | 147 | 0.110 |
Why?
|
| Carcinoma, Adenosquamous | 3 | 2009 | 103 | 0.110 |
Why?
|
| ras Proteins | 2 | 2015 | 772 | 0.110 |
Why?
|
| Self-Assessment | 1 | 2013 | 98 | 0.110 |
Why?
|
| Calcinosis | 1 | 2016 | 426 | 0.110 |
Why?
|
| Bridged-Ring Compounds | 2 | 2020 | 183 | 0.110 |
Why?
|
| Hospice Care | 1 | 2014 | 156 | 0.110 |
Why?
|
| Metformin | 1 | 2016 | 378 | 0.110 |
Why?
|
| Erythrocyte Transfusion | 1 | 2014 | 211 | 0.110 |
Why?
|
| Fluorouracil | 3 | 2013 | 1946 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2005 | 552 | 0.110 |
Why?
|
| Clinical Competence | 4 | 2011 | 1307 | 0.110 |
Why?
|
| Triazoles | 1 | 2017 | 619 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 3265 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 587 | 0.110 |
Why?
|
| Robotic Surgical Procedures | 2 | 2017 | 483 | 0.110 |
Why?
|
| Nitriles | 1 | 2017 | 904 | 0.110 |
Why?
|
| Scientific Misconduct | 1 | 2012 | 21 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 336 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2015 | 585 | 0.100 |
Why?
|
| Preoperative Care | 2 | 2008 | 1529 | 0.100 |
Why?
|
| Oncology Service, Hospital | 1 | 2012 | 48 | 0.100 |
Why?
|
| Mastectomy | 3 | 2009 | 1538 | 0.100 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 868 | 0.100 |
Why?
|
| Cisplatin | 4 | 2013 | 2433 | 0.100 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 1215 | 0.100 |
Why?
|
| Frozen Sections | 2 | 2018 | 105 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 987 | 0.100 |
Why?
|
| Suicide, Assisted | 1 | 2011 | 19 | 0.100 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 328 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2018 | 6225 | 0.100 |
Why?
|
| Patient Education as Topic | 2 | 2008 | 757 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2018 | 650 | 0.100 |
Why?
|
| Serotonin Antagonists | 1 | 2010 | 39 | 0.100 |
Why?
|
| Religion and Medicine | 1 | 2011 | 50 | 0.100 |
Why?
|
| Health Personnel | 2 | 2013 | 631 | 0.090 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2022 | 107 | 0.090 |
Why?
|
| Ethics Consultation | 1 | 2011 | 31 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 4386 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2015 | 1284 | 0.090 |
Why?
|
| Professional-Patient Relations | 1 | 2011 | 129 | 0.090 |
Why?
|
| Registries | 3 | 2015 | 2188 | 0.090 |
Why?
|
| Workload | 1 | 2012 | 199 | 0.090 |
Why?
|
| Quinuclidines | 1 | 2010 | 48 | 0.090 |
Why?
|
| Prevalence | 3 | 2014 | 3271 | 0.090 |
Why?
|
| Isoquinolines | 1 | 2010 | 116 | 0.090 |
Why?
|
| Preimplantation Diagnosis | 1 | 2010 | 47 | 0.090 |
Why?
|
| Life Style | 1 | 2014 | 615 | 0.090 |
Why?
|
| Premenopause | 2 | 2014 | 132 | 0.090 |
Why?
|
| Databases, Factual | 5 | 2019 | 2236 | 0.090 |
Why?
|
| Geriatrics | 1 | 2010 | 97 | 0.090 |
Why?
|
| Fallopian Tubes | 1 | 2010 | 119 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2013 | 502 | 0.090 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2009 | 14 | 0.090 |
Why?
|
| Physicians, Primary Care | 1 | 2010 | 98 | 0.090 |
Why?
|
| CA-19-9 Antigen | 1 | 2010 | 146 | 0.090 |
Why?
|
| Pelvic Bones | 1 | 2010 | 95 | 0.090 |
Why?
|
| Phthalazines | 2 | 2021 | 253 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2019 | 2233 | 0.080 |
Why?
|
| Hormone Antagonists | 1 | 2009 | 101 | 0.080 |
Why?
|
| Mifepristone | 1 | 2009 | 147 | 0.080 |
Why?
|
| Kidney | 1 | 2018 | 2145 | 0.080 |
Why?
|
| Information Dissemination | 1 | 2011 | 273 | 0.080 |
Why?
|
| Social Class | 2 | 2007 | 311 | 0.080 |
Why?
|
| Intestinal Perforation | 1 | 2009 | 102 | 0.080 |
Why?
|
| Education, Medical, Continuing | 1 | 2011 | 254 | 0.080 |
Why?
|
| Primary Prevention | 1 | 2010 | 255 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2014 | 899 | 0.080 |
Why?
|
| Communication | 2 | 2013 | 880 | 0.080 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2018 | 235 | 0.080 |
Why?
|
| Ki-67 Antigen | 2 | 2020 | 670 | 0.080 |
Why?
|
| Fatigue | 3 | 2015 | 1239 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 2485 | 0.080 |
Why?
|
| Fellowships and Scholarships | 1 | 2012 | 391 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2020 | 1434 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1153 | 0.080 |
Why?
|
| Obstetrics | 1 | 2010 | 222 | 0.080 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 86 | 0.080 |
Why?
|
| Radiotherapy | 3 | 2010 | 1827 | 0.080 |
Why?
|
| MutS Homolog 2 Protein | 3 | 2014 | 178 | 0.080 |
Why?
|
| MutL Protein Homolog 1 | 3 | 2014 | 206 | 0.080 |
Why?
|
| Gene Expression | 3 | 2020 | 3568 | 0.080 |
Why?
|
| Robotics | 1 | 2011 | 359 | 0.070 |
Why?
|
| Marital Therapy | 1 | 2006 | 5 | 0.070 |
Why?
|
| Menopause, Premature | 1 | 2007 | 16 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2010 | 293 | 0.070 |
Why?
|
| Sex Counseling | 1 | 2006 | 17 | 0.070 |
Why?
|
| Physician-Patient Relations | 2 | 2011 | 802 | 0.070 |
Why?
|
| Salpingostomy | 1 | 2006 | 8 | 0.070 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2010 | 436 | 0.070 |
Why?
|
| Comorbidity | 3 | 2023 | 2394 | 0.070 |
Why?
|
| Male | 17 | 2019 | 123339 | 0.070 |
Why?
|
| Models, Economic | 2 | 2021 | 101 | 0.070 |
Why?
|
| Pyrimidines | 3 | 2021 | 3538 | 0.070 |
Why?
|
| Sexual Behavior | 2 | 2005 | 309 | 0.070 |
Why?
|
| Survival Analysis | 8 | 2014 | 9198 | 0.070 |
Why?
|
| Patient Safety | 1 | 2012 | 651 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2020 | 5188 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 4 | 2020 | 3988 | 0.070 |
Why?
|
| Biomarkers, Tumor | 4 | 2020 | 10354 | 0.070 |
Why?
|
| Markov Chains | 3 | 2011 | 175 | 0.070 |
Why?
|
| Disease Progression | 1 | 2017 | 6699 | 0.070 |
Why?
|
| Social Support | 4 | 2013 | 560 | 0.070 |
Why?
|
| Carcinoma, Large Cell | 1 | 2005 | 94 | 0.060 |
Why?
|
| Gene Amplification | 2 | 2006 | 731 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 7580 | 0.060 |
Why?
|
| Carboplatin | 3 | 2017 | 824 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 2631 | 0.060 |
Why?
|
| Uterus | 1 | 2009 | 674 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2009 | 666 | 0.060 |
Why?
|
| Mesenteric Veins | 1 | 2004 | 73 | 0.060 |
Why?
|
| Vacuum | 1 | 2004 | 42 | 0.060 |
Why?
|
| Bevacizumab | 2 | 2019 | 939 | 0.060 |
Why?
|
| Case-Control Studies | 5 | 2016 | 6106 | 0.060 |
Why?
|
| Alopecia | 1 | 2004 | 127 | 0.060 |
Why?
|
| DNA Mutational Analysis | 3 | 2015 | 2281 | 0.060 |
Why?
|
| Organoplatinum Compounds | 2 | 2020 | 704 | 0.060 |
Why?
|
| Medical Records | 3 | 2014 | 414 | 0.060 |
Why?
|
| Anorexia | 2 | 2015 | 143 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 5010 | 0.060 |
Why?
|
| Progestins | 2 | 2019 | 87 | 0.060 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 229 | 0.060 |
Why?
|
| Health Surveys | 2 | 2019 | 410 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2003 | 79 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2008 | 510 | 0.060 |
Why?
|
| Viral Vaccines | 1 | 2006 | 305 | 0.060 |
Why?
|
| Papillomavirus Vaccines | 1 | 2006 | 195 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2004 | 500 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 153 | 0.050 |
Why?
|
| Perioperative Care | 2 | 2019 | 452 | 0.050 |
Why?
|
| Monte Carlo Method | 3 | 2011 | 672 | 0.050 |
Why?
|
| Patient Selection | 1 | 2010 | 2061 | 0.050 |
Why?
|
| Carcinoma, Small Cell | 1 | 2005 | 408 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 4348 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2006 | 612 | 0.050 |
Why?
|
| Immunohistochemistry | 6 | 2013 | 7557 | 0.050 |
Why?
|
| Portal Vein | 1 | 2004 | 356 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2010 | 1412 | 0.050 |
Why?
|
| Membrane Proteins | 3 | 2020 | 2813 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 1229 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2006 | 1759 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2017 | 502 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2003 | 481 | 0.050 |
Why?
|
| Pancreatectomy | 2 | 2020 | 654 | 0.050 |
Why?
|
| Paclitaxel | 3 | 2017 | 1998 | 0.050 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 67 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2018 | 2802 | 0.050 |
Why?
|
| Depression | 3 | 2015 | 1715 | 0.050 |
Why?
|
| Ostomy | 1 | 2020 | 19 | 0.050 |
Why?
|
| Retinal Dehydrogenase | 1 | 2020 | 91 | 0.050 |
Why?
|
| Logistic Models | 3 | 2016 | 3450 | 0.050 |
Why?
|
| Incidence | 4 | 2016 | 5712 | 0.050 |
Why?
|
| Machine Learning | 1 | 2022 | 321 | 0.050 |
Why?
|
| Predictive Value of Tests | 4 | 2013 | 4902 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2017 | 6040 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 160 | 0.050 |
Why?
|
| Neoplasm Proteins | 2 | 2013 | 3236 | 0.040 |
Why?
|
| Splenectomy | 1 | 2020 | 157 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 2 | 2005 | 1350 | 0.040 |
Why?
|
| Pregnancy | 4 | 2019 | 7552 | 0.040 |
Why?
|
| Deductibles and Coinsurance | 1 | 2019 | 11 | 0.040 |
Why?
|
| Data Collection | 2 | 2013 | 626 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2010 | 1411 | 0.040 |
Why?
|
| Cyclophosphamide | 3 | 2017 | 3084 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2023 | 1033 | 0.040 |
Why?
|
| Diaphragm | 1 | 2020 | 181 | 0.040 |
Why?
|
| Wound Healing | 1 | 2004 | 813 | 0.040 |
Why?
|
| Lymphatic Metastasis | 4 | 2010 | 4847 | 0.040 |
Why?
|
| Siblings | 1 | 2019 | 289 | 0.040 |
Why?
|
| Sexual Health | 1 | 2018 | 15 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 4949 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1999 | 173 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2015 | 1338 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1999 | 203 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 428 | 0.040 |
Why?
|
| Pyrroles | 1 | 2021 | 584 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2000 | 430 | 0.040 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2017 | 35 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 645 | 0.040 |
Why?
|
| Algorithms | 2 | 2022 | 3891 | 0.040 |
Why?
|
| Mammaplasty | 1 | 2004 | 780 | 0.040 |
Why?
|
| Body Image | 1 | 2018 | 141 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2005 | 2297 | 0.040 |
Why?
|
| Carcinoma in Situ | 1 | 2000 | 485 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 862 | 0.040 |
Why?
|
| Coloring Agents | 1 | 2017 | 235 | 0.040 |
Why?
|
| Indocyanine Green | 1 | 2017 | 117 | 0.040 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 623 | 0.030 |
Why?
|
| Nuclear Proteins | 3 | 2014 | 3318 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 4979 | 0.030 |
Why?
|
| ROC Curve | 1 | 1999 | 1180 | 0.030 |
Why?
|
| Pain | 2 | 2015 | 1674 | 0.030 |
Why?
|
| Adiponectin | 1 | 2016 | 162 | 0.030 |
Why?
|
| Linear Models | 1 | 2019 | 1090 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 3757 | 0.030 |
Why?
|
| Laparotomy | 1 | 2017 | 211 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 848 | 0.030 |
Why?
|
| Intestines | 1 | 2020 | 688 | 0.030 |
Why?
|
| Hospices | 1 | 2015 | 51 | 0.030 |
Why?
|
| Attitude to Death | 1 | 2016 | 100 | 0.030 |
Why?
|
| Parity | 2 | 2006 | 138 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2005 | 2519 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2002 | 1368 | 0.030 |
Why?
|
| Weight Loss | 1 | 2019 | 630 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 755 | 0.030 |
Why?
|
| Niacinamide | 1 | 2017 | 421 | 0.030 |
Why?
|
| Needs Assessment | 2 | 2008 | 233 | 0.030 |
Why?
|
| Health Care Surveys | 2 | 2008 | 431 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2021 | 1177 | 0.030 |
Why?
|
| DNA-Binding Proteins | 3 | 2014 | 4793 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2010 | 1532 | 0.030 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2014 | 47 | 0.030 |
Why?
|
| Capecitabine | 2 | 2006 | 388 | 0.030 |
Why?
|
| Constipation | 1 | 2015 | 177 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2018 | 628 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2014 | 83 | 0.030 |
Why?
|
| Imatinib Mesylate | 2 | 2012 | 1665 | 0.030 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2015 | 134 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2020 | 1009 | 0.030 |
Why?
|
| General Surgery | 2 | 2007 | 328 | 0.030 |
Why?
|
| Melanoma | 1 | 2010 | 5321 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2017 | 581 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2019 | 1308 | 0.030 |
Why?
|
| Culture | 1 | 2013 | 100 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2019 | 1991 | 0.030 |
Why?
|
| Benzamides | 2 | 2012 | 1834 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2013 | 188 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2014 | 238 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1948 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4329 | 0.030 |
Why?
|
| Child | 4 | 2019 | 29146 | 0.030 |
Why?
|
| Stomatitis | 1 | 2013 | 183 | 0.030 |
Why?
|
| Psychotherapy | 1 | 2014 | 246 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 437 | 0.030 |
Why?
|
| Classification | 1 | 2011 | 41 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 1166 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2013 | 560 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2014 | 435 | 0.030 |
Why?
|
| Cancer Care Facilities | 2 | 2008 | 884 | 0.020 |
Why?
|
| Germ-Line Mutation | 2 | 2007 | 1047 | 0.020 |
Why?
|
| DNA Mismatch Repair | 1 | 2013 | 268 | 0.020 |
Why?
|
| Cell Death | 1 | 2013 | 673 | 0.020 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 845 | 0.020 |
Why?
|
| Genomics | 1 | 2022 | 2746 | 0.020 |
Why?
|
| Research Report | 1 | 2012 | 146 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 975 | 0.020 |
Why?
|
| Heterozygote | 1 | 2014 | 1016 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2013 | 428 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 3482 | 0.020 |
Why?
|
| Pubic Bone | 1 | 2010 | 16 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2011 | 183 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 855 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2010 | 133 | 0.020 |
Why?
|
| Acetabulum | 1 | 2010 | 39 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2006 | 2233 | 0.020 |
Why?
|
| Diarrhea | 1 | 2013 | 689 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 2012 | 302 | 0.020 |
Why?
|
| Sacrum | 1 | 2010 | 134 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 5057 | 0.020 |
Why?
|
| Mass Screening | 1 | 2017 | 1505 | 0.020 |
Why?
|
| State Health Plans | 1 | 2008 | 8 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2015 | 996 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 1907 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2011 | 6896 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 602 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2009 | 342 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 622 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 4770 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 1889 | 0.020 |
Why?
|
| Bone Density | 1 | 2010 | 470 | 0.020 |
Why?
|
| Retroperitoneal Space | 1 | 2006 | 145 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2013 | 1516 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 5385 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2006 | 5123 | 0.020 |
Why?
|
| Pregnancy Complications | 1 | 2011 | 524 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 826 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2007 | 576 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2006 | 102 | 0.020 |
Why?
|
| Menstruation Disturbances | 1 | 2005 | 22 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 212 | 0.020 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2004 | 37 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 1947 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 2288 | 0.020 |
Why?
|
| Myometrium | 1 | 2004 | 79 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2006 | 1208 | 0.020 |
Why?
|
| Occlusive Dressings | 1 | 2004 | 14 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2004 | 247 | 0.020 |
Why?
|
| Decision Trees | 1 | 2004 | 178 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 2505 | 0.010 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2005 | 74 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2014 | 2673 | 0.010 |
Why?
|
| Melphalan | 1 | 2007 | 834 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2007 | 1392 | 0.010 |
Why?
|
| Animals | 2 | 2020 | 59577 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2009 | 799 | 0.010 |
Why?
|
| Outpatients | 1 | 2006 | 461 | 0.010 |
Why?
|
| Reproduction | 1 | 2005 | 253 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 482 | 0.010 |
Why?
|
| Mothers | 1 | 2006 | 411 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 3846 | 0.010 |
Why?
|
| Genome, Human | 1 | 2010 | 1868 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 1556 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2006 | 669 | 0.010 |
Why?
|
| Risk | 1 | 2006 | 1974 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 8230 | 0.010 |
Why?
|
| Epithelium | 1 | 2003 | 720 | 0.010 |
Why?
|
| Recurrence | 1 | 2009 | 4785 | 0.010 |
Why?
|
| Suction | 1 | 2000 | 104 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 2421 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 13310 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2004 | 656 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 4556 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 1999 | 279 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 5158 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1999 | 306 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2004 | 708 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 4323 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 1880 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 34456 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 14586 | 0.010 |
Why?
|